RADNOR, Pa., Sept. 19, 2022 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is notifying investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. (“Kiromic”) in the United States District Court for the Southern District of New York. KRBP. The lawsuit alleges Kiromic’s violations of federal securities laws, including omissions and fraudulent misrepresentations regarding the company’s business, operations and prospects. As a result of Kiromic’s materially misleading public statements and omissions, Kiromic’s investors have suffered significant losses.

CLICK HERE TO SUBMIT YOUR KIROMIC LOSSES. YOU CAN ALSO CLICK OR COPY AND PASTE THE FOLLOWING LINK INTO YOUR BROWSER: https://www.ktmc.com/new-cases/kiromic-biopharma-inc?utm_source=PR&utm_medium=link&utm_campaign=kiromic&mktm=r

CAN’T WATCH THIS VIDEO? YOU’RE WELCOME CLICK HERE

LIMIT FOR THE PLAINTIFF: 4 OCTOBER 2022

PRICE PERIOD: COMMON SHARES PURCHASED BETWEEN JUNE 25, 2021 AND AUGUST 5, 2022

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
Jonathan Naji, Esq. at (484) 270-1453 or email at [email protected]

Kessler Topaz is one of the world’s leading advocates for protecting the public from corporate fraud and other wrongdoing. Our securities fraud litigators are consistently recognized individually as leaders in the field, and our firm is feared and respected by both the defense and the Insurance Board. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

KIROMIC’S ALLEGED MISCONDUCT
In late June 2021, Kiromic conducted an initial public offering (IPO) which closed on July 2, 2021. At the time of the IPO, Kiromic presented itself as a target discovery and gene editing company using artificial intelligence to develop immunotherapy products. Although Kiromic had no immunotherapy products on the market at the time, it had applications to begin human clinical trials for two new drugs…